Research programme: bispecific and trispecific anti-cancer antibodies - Antibody Therapeutics
Alternative Names: Bispecific anti-cancer antibodies - Antibody Therapeutics; Trispecific anti-cancer antibodies - Antibody TherapeuticsLatest Information Update: 30 Aug 2021
At a glance
- Originator Antibody Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Adenocarcinoma; Breast cancer; Lung cancer; Solid tumours
Most Recent Events
- 30 Aug 2021 Bispecific and trispecific anti-cancer antibodies - Antibody Therapeutics are available for licensing as of 30 Aug 2021. https://www.antibodytherapeutics.com/company/
- 30 Aug 2021 Preclinical trials in Adenocarcinoma in USA (Parenteral) prior to August 2021 (Antibody Therapeutics pipeline, August 2021)
- 30 Aug 2021 Preclinical trials in Breast cancer in USA (Parenteral) prior to August 2021 (Antibody Therapeutics pipeline, August 2021)